These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29786888)

  • 21.
    Kim J; Francis DM; Thomas SN
    Nanomaterials (Basel); 2021 Feb; 11(2):. PubMed ID: 33673289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioresponsive and immunotherapeutic nanomaterials to remodel tumor microenvironment for enhanced immune checkpoint blockade.
    Fang T; Cao X; Wang L; Chen M; Deng Y; Chen G
    Bioact Mater; 2024 Feb; 32():530-542. PubMed ID: 38026439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cell membrane cloaking tumor microenvironment-responsive nanoparticles with a smart "membrane escape mechanism" for enhanced immune-chemotherapy of melanoma.
    Li X; Zhang W; Lin J; Wu H; Yao Y; Zhang J; Yang C
    Biomater Sci; 2021 May; 9(9):3453-3464. PubMed ID: 33949434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The application of nanotechnology in immune checkpoint blockade for cancer treatment.
    Deng H; Zhang Z
    J Control Release; 2018 Nov; 290():28-45. PubMed ID: 30287266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An injectable hydrogel using an immunomodulating gelator for amplified tumor immunotherapy by blocking the arginase pathway.
    Ren X; Wang N; Zhou Y; Song A; Jin G; Li Z; Luan Y
    Acta Biomater; 2021 Apr; 124():179-190. PubMed ID: 33524560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases.
    Xiang Z; Yu Y
    Front Med; 2019 Feb; 13(1):24-31. PubMed ID: 30659409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.
    Menderes G; Hicks C; Black JD; Schwab CL; Santin AD
    Expert Opin Biol Ther; 2016 Aug; 16(8):989-1004. PubMed ID: 27070175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cas9-edited immune checkpoint blockade PD-1 DNA polyaptamer hydrogel for cancer immunotherapy.
    Lee J; Le QV; Yang G; Oh YK
    Biomaterials; 2019 Oct; 218():119359. PubMed ID: 31349094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physical- and Chemical-Dually ROS-Responsive Nano-in-Gel Platforms with Sequential Release of OX40 Agonist and PD-1 Inhibitor for Augmented Combination Immunotherapy.
    Fu Y; Huang Y; Li P; Wang L; Tang Z; Liu X; Bian X; Wu S; Wang X; Zhu B; Yu Y; Jiang J; Li C
    Nano Lett; 2023 Feb; 23(4):1424-1434. PubMed ID: 36779813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
    Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
    Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Era of Checkpoint Inhibition: Lessons Learned from Melanoma.
    Paschen A; Schadendorf D
    Recent Results Cancer Res; 2020; 214():169-187. PubMed ID: 31473853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
    Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
    Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chlorin-Based Nanoscale Metal-Organic Framework Systemically Rejects Colorectal Cancers via Synergistic Photodynamic Therapy and Checkpoint Blockade Immunotherapy.
    Lu K; He C; Guo N; Chan C; Ni K; Weichselbaum RR; Lin W
    J Am Chem Soc; 2016 Sep; 138(38):12502-10. PubMed ID: 27575718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma.
    Zhang N; Song J; Liu Y; Liu M; Zhang L; Sheng D; Deng L; Yi H; Wu M; Zheng Y; Wang Z; Yang Z
    J Control Release; 2019 Jul; 306():15-28. PubMed ID: 31132380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells.
    Yong SB; Chung JY; Song Y; Kim J; Ra S; Kim YH
    Biomaterials; 2019 Oct; 219():119401. PubMed ID: 31398571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospects for combining immune checkpoint blockade with PARP inhibition.
    Li A; Yi M; Qin S; Chu Q; Luo S; Wu K
    J Hematol Oncol; 2019 Sep; 12(1):98. PubMed ID: 31521196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment.
    Feng B; Zhou F; Hou B; Wang D; Wang T; Fu Y; Ma Y; Yu H; Li Y
    Adv Mater; 2018 Sep; 30(38):e1803001. PubMed ID: 30063262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
    Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
    Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.